Literature DB >> 16983074

Cardiac myosin missense mutations cause dilated cardiomyopathy in mouse models and depress molecular motor function.

Joachim P Schmitt1, Edward P Debold, Ferhaan Ahmad, Amy Armstrong, Andrea Frederico, David A Conner, Ulrike Mende, Martin J Lohse, David Warshaw, Christine E Seidman, J G Seidman.   

Abstract

Dilated cardiomyopathy (DCM) leads to heart failure, a leading cause of death in industrialized nations. Approximately 30% of DCM cases are genetic in origin, with some resulting from point mutations in cardiac myosin, the molecular motor of the heart. The effects of these mutations on myosin's molecular mechanics have not been determined. We have engineered two murine models characterizing the physiological, cellular, and molecular effects of DCM-causing missense mutations (S532P and F764L) in the alpha-cardiac myosin heavy chain and compared them with WT mice. Mutant mice developed morphological and functional characteristics of DCM consistent with the human phenotypes. Contractile function of isolated myocytes was depressed and preceded left ventricular dilation and reduced fractional shortening. In an in vitro motility assay, both mutant cardiac myosins exhibited a reduced ability to translocate actin (V(actin)) but had similar force-generating capacities. Actin-activated ATPase activities were also reduced. Single-molecule laser trap experiments revealed that the lower V(actin) in the S532P mutant was due to a reduced ability of the motor to generate a step displacement and an alteration of the kinetics of its chemomechanical cycle. These results suggest that the depressed molecular function in cardiac myosin may initiate the events that cause the heart to remodel and become pathologically dilated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16983074      PMCID: PMC1599993          DOI: 10.1073/pnas.0606383103

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  Computer-assisted tracking of actin filament motility.

Authors:  S S Work; D M Warshaw
Journal:  Anal Biochem       Date:  1992-05-01       Impact factor: 3.365

2.  Smooth muscle and skeletal muscle myosins produce similar unitary forces and displacements in the laser trap.

Authors:  W H Guilford; D E Dupuis; G Kennedy; J Wu; J B Patlak; D M Warshaw
Journal:  Biophys J       Date:  1997-03       Impact factor: 4.033

3.  Cardiac V1 and V3 myosins differ in their hydrolytic and mechanical activities in vitro.

Authors:  P VanBuren; D E Harris; N R Alpert; D M Warshaw
Journal:  Circ Res       Date:  1995-08       Impact factor: 17.367

4.  Maximal actomyosin ATPase activity and in vitro myosin motility are unaltered in human mitral regurgitation heart failure.

Authors:  T T Nguyen; E Hayes; L A Mulieri; B J Leavitt; H E ter Keurs; N R Alpert; D M Warshaw
Journal:  Circ Res       Date:  1996-08       Impact factor: 17.367

5.  The essential light chain is required for full force production by skeletal muscle myosin.

Authors:  P VanBuren; G S Waller; D E Harris; K M Trybus; D M Warshaw; S Lowey
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

6.  Neonatal cardiomyopathy in mice homozygous for the Arg403Gln mutation in the alpha cardiac myosin heavy chain gene.

Authors:  D Fatkin; M E Christe; O Aristizabal; B K McConnell; S Srinivasan; F J Schoen; C E Seidman; D H Turnbull; J G Seidman
Journal:  J Clin Invest       Date:  1999-01       Impact factor: 14.808

7.  Calcium regulation of thin filament movement in an in vitro motility assay.

Authors:  E Homsher; B Kim; A Bobkova; L S Tobacman
Journal:  Biophys J       Date:  1996-04       Impact factor: 4.033

8.  Structure of the actin-myosin complex and its implications for muscle contraction.

Authors:  I Rayment; H M Holden; M Whittaker; C B Yohn; M Lorenz; K C Holmes; R A Milligan
Journal:  Science       Date:  1993-07-02       Impact factor: 47.728

9.  Structural interpretation of the mutations in the beta-cardiac myosin that have been implicated in familial hypertrophic cardiomyopathy.

Authors:  I Rayment; H M Holden; J R Sellers; L Fananapazir; N D Epstein
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

10.  A mouse model of familial hypertrophic cardiomyopathy.

Authors:  A A Geisterfer-Lowrance; M Christe; D A Conner; J S Ingwall; F J Schoen; C E Seidman; J G Seidman
Journal:  Science       Date:  1996-05-03       Impact factor: 47.728

View more
  43 in total

1.  Fluorescence spectra of cardiac myosin and in vivo experiment: studies on daunorubicin-induced cardiotoxicity.

Authors:  Yang Liu; Chi Chen; Xiaoxiang Duan; Wenting Ma; Man Wang; Mengyi Tu; Ying Chen
Journal:  Iran J Basic Med Sci       Date:  2015-12       Impact factor: 2.699

2.  Converter domain mutations in myosin alter structural kinetics and motor function.

Authors:  Laura K Gunther; John A Rohde; Wanjian Tang; Shane D Walton; William C Unrath; Darshan V Trivedi; Joseph M Muretta; David D Thomas; Christopher M Yengo
Journal:  J Biol Chem       Date:  2018-12-05       Impact factor: 5.157

3.  DDiT4L promotes autophagy and inhibits pathological cardiac hypertrophy in response to stress.

Authors:  Bridget Simonson; Vinita Subramanya; Mun Chun Chan; Aifeng Zhang; Hannabeth Franchino; Filomena Ottaviano; Manoj K Mishra; Ashley C Knight; Danielle Hunt; Ionita Ghiran; Tejvir S Khurana; Maria I Kontaridis; Anthony Rosenzweig; Saumya Das
Journal:  Sci Signal       Date:  2017-02-28       Impact factor: 8.192

Review 4.  Understanding cardiomyopathy phenotypes based on the functional impact of mutations in the myosin motor.

Authors:  Jeffrey R Moore; Leslie Leinwand; David M Warshaw
Journal:  Circ Res       Date:  2012-07-20       Impact factor: 17.367

5.  Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin.

Authors:  Christopher N Toepfer; Hiroko Wakimoto; Amanda C Garfinkel; Barbara McDonough; Dan Liao; Jianming Jiang; Angela C Tai; Joshua M Gorham; Ida G Lunde; Mingyue Lun; Thomas L Lynch; James W McNamara; Sakthivel Sadayappan; Charles S Redwood; Hugh C Watkins; Jonathan G Seidman; Christine E Seidman
Journal:  Sci Transl Med       Date:  2019-01-23       Impact factor: 17.956

6.  The mesa trail and the interacting heads motif of myosin II.

Authors:  John L Woodhead; Roger Craig
Journal:  Arch Biochem Biophys       Date:  2019-12-13       Impact factor: 4.013

7.  Chromatin regulation by Brg1 underlies heart muscle development and disease.

Authors:  Calvin T Hang; Jin Yang; Pei Han; Hsiu-Ling Cheng; Ching Shang; Euan Ashley; Bin Zhou; Ching-Pin Chang
Journal:  Nature       Date:  2010-07-01       Impact factor: 49.962

8.  It's never too early to look: subclinical disease in sarcomeric dilated cardiomyopathy.

Authors:  Jil C Tardiff
Journal:  Circ Cardiovasc Genet       Date:  2012-10-01

9.  Elevated rates of force development and MgATP binding in F764L and S532P myosin mutations causing dilated cardiomyopathy.

Authors:  Bradley M Palmer; Joachim P Schmitt; Christine E Seidman; J G Seidman; Yuan Wang; Stephen P Bell; Martin M Lewinter; David W Maughan
Journal:  J Mol Cell Cardiol       Date:  2013-01-08       Impact factor: 5.000

Review 10.  Genetic mutations and mechanisms in dilated cardiomyopathy.

Authors:  Elizabeth M McNally; Jessica R Golbus; Megan J Puckelwartz
Journal:  J Clin Invest       Date:  2013-01-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.